IMMVF: AI 评分 39/100 — AI 分析 (4月 2026)

Immunovia AB (publ) is a diagnostic company focused on early detection of cancer through blood-based tests. Their primary product, IMMray PanCan-d, aims to improve outcomes for pancreatic cancer patients.

Key Facts: AI Score: 39/100 Sector: Healthcare

公司概况

概要：

Immunovia AB (publ) develops and commercializes blood-based diagnostic tests, primarily IMMray PanCan-d for early pancreatic cancer detection, operating in the competitive medical diagnostics market with a focus on international expansion and lung cancer research projects, while facing financial challenges reflected in negative profit margins.

IMMVF是做什么的？

Immunovia AB (publ), established in 2007 and headquartered in Lund, Sweden, is a diagnostic company dedicated to the development and commercialization of innovative blood tests. The company's flagship product, IMMray PanCan-d, is a blood-based test designed for the early detection of pancreatic cancer, a disease known for its aggressive nature and poor prognosis when diagnosed late. Immunovia's mission is to improve survival rates and quality of life for patients by enabling earlier diagnosis and treatment interventions. Beyond pancreatic cancer, Immunovia is also engaged in research projects focused on lung cancer, indicating a broader ambition to expand its diagnostic capabilities across multiple cancer types. The company operates both in Sweden and internationally, reflecting its commitment to making its diagnostic solutions accessible to patients worldwide. Immunovia's business model centers around the development, validation, and commercialization of proprietary diagnostic tests, leveraging its expertise in proteomics and biomarker discovery. The company faces competition from established players in the diagnostics industry, as well as emerging companies developing novel cancer detection technologies. With a small team of 9 employees, Immunovia operates with a lean structure, focusing its resources on research, development, and commercialization efforts.

IMMVF的投资论点是什么？

Immunovia AB (publ) presents a high-risk, high-reward investment opportunity centered on its IMMray PanCan-d test for early pancreatic cancer detection. The potential value driver is the successful commercialization and adoption of IMMray PanCan-d, addressing a critical unmet need in cancer diagnostics. Key catalysts include positive clinical trial results, regulatory approvals, and successful market penetration in key geographic regions. However, the company's negative profit margin of -21332.5% and gross margin of -2337.6% highlight significant financial challenges. The company's future hinges on securing additional funding and achieving profitability. Investors should closely monitor the company's cash burn rate, revenue growth, and competitive landscape.

IMMVF在哪个行业运营？

Immunovia operates in the medical diagnostics industry, a sector experiencing rapid growth driven by technological advancements and increasing demand for early and accurate disease detection. The market for cancer diagnostics is particularly large and growing, fueled by an aging population and rising cancer incidence rates. Immunovia's focus on early pancreatic cancer detection positions it within a niche segment of this market. Competitors include companies developing liquid biopsy tests and other diagnostic modalities. The industry is characterized by intense competition, stringent regulatory requirements, and the need for continuous innovation.

Medical - Diagnostics & Research

Healthcare

IMMVF有哪些增长机遇？

Expansion into New Geographic Markets: Immunovia has the opportunity to expand its commercial operations into new geographic markets, particularly in regions with high pancreatic cancer incidence rates and unmet diagnostic needs. This expansion could involve establishing partnerships with local distributors, conducting clinical trials in new regions, and obtaining regulatory approvals in new countries. Successful geographic expansion could significantly increase Immunovia's revenue and market share. Timeline: Ongoing.
Development of New Diagnostic Tests: Immunovia can leverage its expertise in proteomics and biomarker discovery to develop new diagnostic tests for other types of cancer and diseases. This diversification of its product portfolio would reduce its reliance on IMMray PanCan-d and create new revenue streams. The company's research projects focused on lung cancer represent a potential first step in this direction. Timeline: Ongoing.
Strategic Partnerships and Collaborations: Immunovia can pursue strategic partnerships and collaborations with pharmaceutical companies, research institutions, and healthcare providers to accelerate the development and commercialization of its diagnostic tests. These partnerships could provide access to funding, expertise, and distribution channels. For example, a partnership with a pharmaceutical company developing a new pancreatic cancer drug could help to drive adoption of IMMray PanCan-d. Timeline: Ongoing.
Increased Awareness and Adoption of IMMray PanCan-d: Immunovia can invest in marketing and educational initiatives to increase awareness and adoption of IMMray PanCan-d among physicians and patients. This could involve presenting clinical data at medical conferences, publishing articles in peer-reviewed journals, and conducting direct-to-consumer advertising campaigns. Increased awareness and adoption of IMMray PanCan-d would drive revenue growth and improve patient outcomes. Timeline: Ongoing.
Leveraging AI and Machine Learning: Immunovia can integrate artificial intelligence (AI) and machine learning (ML) technologies into its diagnostic development process to improve the accuracy and efficiency of its tests. AI/ML can be used to identify new biomarkers, optimize test algorithms, and personalize diagnostic results. This would enhance the value proposition of Immunovia's tests and give it a competitive advantage. Timeline: Ongoing.

Market capitalization of $0.01 billion, indicating a micro-cap company with significant growth potential but also higher risk.
P/E ratio of -0.58, reflecting current losses and the company's focus on growth and future profitability.
Profit Margin of -21332.5%, highlighting the company's current financial struggles and the need for improved cost management and revenue generation.
Gross Margin of -2337.6%, indicating challenges in the cost of goods sold and pricing strategies.
Beta of 2.77, suggesting high volatility compared to the overall market, reflecting the speculative nature of the stock and its sensitivity to market fluctuations.

IMMVF提供哪些产品和服务？

Develop blood-based diagnostic tests.
Focus on early detection of pancreatic cancer.
Commercialize IMMray PanCan-d test.
Conduct research projects for lung cancer.
Operate in Sweden and internationally.
Aim to improve survival rates for cancer patients.

IMMVF如何赚钱？

Develop proprietary diagnostic tests.
Commercialize tests through direct sales and partnerships.
Generate revenue from test sales.
Invest in research and development for new tests.

Hospitals and clinics.
Physicians and oncologists.
Patients at risk of pancreatic cancer.
Healthcare providers.

Proprietary IMMray PanCan-d test.
Expertise in proteomics and biomarker discovery.
Focus on early cancer detection.
Research projects for lung cancer.

什么因素可能推动IMMVF股价上涨？

Upcoming: Positive results from ongoing clinical trials of IMMray PanCan-d.
Ongoing: Expansion of commercial operations into new geographic markets.
Ongoing: Development of new diagnostic tests for other cancers.
Ongoing: Strategic partnerships and collaborations with pharmaceutical companies and healthcare providers.

IMMVF的主要风险是什么？

Ongoing: Intense competition from established diagnostics companies.
Potential: Regulatory hurdles and approval processes for diagnostic tests.
Potential: Reimbursement challenges from healthcare payers.
Ongoing: Negative profit and gross margins, requiring additional funding.
Potential: Technological advancements and disruptive innovations in cancer diagnostics.

IMMVF的核心优势是什么？

Proprietary IMMray PanCan-d test for early pancreatic cancer detection.
Focus on a critical unmet need in cancer diagnostics.
Expertise in proteomics and biomarker discovery.
International operations.

IMMVF的劣势是什么？

Negative profit and gross margins.
Small company size with limited resources.
Reliance on a single product (IMMray PanCan-d).
Limited market penetration.

IMMVF有哪些机遇？

Expansion into new geographic markets.
Development of new diagnostic tests for other cancers.
Strategic partnerships and collaborations.
Increased awareness and adoption of IMMray PanCan-d.

IMMVF面临哪些威胁？

Competition from established diagnostics companies.
Regulatory hurdles and approval processes.
Technological advancements and disruptive innovations.
Reimbursement challenges from healthcare payers.

IMMVF的竞争对手是谁？

AnPac Bio-Medical Science Co Ltd — Focuses on early cancer screening and detection using different technologies. — (ANPCY)
Asan Pharmaceutical Co Ltd — Develops and manufactures pharmaceutical products and diagnostic reagents. — (ASAPF)
CalciMedica Inc — Focuses on developing novel therapies for severe inflammatory and autoimmune diseases. — (CLCS)
Medigene AG — Develops immunotherapies to treat cancer. — (MBGNF)
OpGen Inc — Focuses on developing molecular information solutions for combating infectious disease. — (OPGN)

Key Metrics

MoonshotScore: 39/100

Company Profile

CEO: Jeff Borcherding
Headquarters: Lund, SE
Employees: 9
Founded: 2019

AI Insight

AI analysis pending for IMMVF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Immunovia AB (publ) do?

Immunovia AB (publ) is a diagnostic company that develops and commercializes blood-based tests for the early detection of cancer, with a primary focus on pancreatic cancer. Its flagship product, IMMray PanCan-d, is designed to detect pancreatic cancer at an early stage, improving patient outcomes. The company also conducts research projects for lung cancer, indicating a broader ambition to expand its diagnostic capabilities. Immunovia operates in Sweden and internationally, aiming to make its diagnostic solutions accessible to patients worldwide.

What do analysts say about IMMVF stock?

AI analysis is pending for IMMVF. Therefore, no analyst consensus, valuation metrics, or growth considerations are currently available. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. The company's financial performance and future prospects should be carefully evaluated based on available information and industry trends.

What are the main risks for IMMVF?

The main risks for Immunovia AB (publ) include intense competition from established diagnostics companies, regulatory hurdles and approval processes for its diagnostic tests, and potential reimbursement challenges from healthcare payers. The company's negative profit and gross margins also pose a significant risk, requiring it to secure additional funding to sustain its operations. Additionally, technological advancements and disruptive innovations in cancer diagnostics could render its products obsolete.

How does Immunovia AB (publ) manage patent expiration risks?

As a diagnostic company, Immunovia AB (publ) faces risks associated with patent protection for its IMMray PanCan-d test and other diagnostic technologies. While specific details on their patent portfolio are unavailable, the company likely employs strategies such as filing patents on novel biomarkers, test algorithms, and methods of use. Managing patent expiration involves continuously innovating and developing new diagnostic solutions to maintain a competitive edge and protect its intellectual property. The company must also monitor the competitive landscape for potential patent infringement and be prepared to defend its patents if necessary.

What revenue streams does Immunovia AB (publ) have in healthcare?

Immunovia AB (publ)'s primary revenue stream is currently derived from the commercialization of its IMMray PanCan-d test for early pancreatic cancer detection. While specific revenue figures are not provided, the company generates income from the sale of this test to hospitals, clinics, and healthcare providers. As Immunovia expands its product portfolio and geographic reach, it anticipates diversifying its revenue streams through the introduction of new diagnostic tests and the establishment of partnerships with pharmaceutical companies and research institutions. The success of these efforts will be crucial for the company's long-term financial sustainability.